Littlewood J M, Kelleher J, Walters M P, Johnson A W
Regional Cystic Fibrosis Unit, St. James's University Hospital, Leeds, U.K.
J Pediatr Gastroenterol Nutr. 1988;7 Suppl 1:S22-9. doi: 10.1097/00005176-198811001-00006.
Over the past 5 years, the Leeds Regional Cystic Fibrosis (CF) Unit has provided comprehensive annual assessments of CF patients that include dietary assessments and fat absorption studies. Enteric-coated microsphere pancreatic enzyme preparations (microsphere preparations) were compared to conventional enzymes as therapeutic agents for these patients. Presently in the U.K., two microsphere preparations are licensed for use and a further two products are likely to receive licenses in the near future. The success of these preparations is dependent on the ability of the microsphere coating to resist dissolution until the pH exceeds approximately 5.5 and thus prevent inactivation of lipase in the acid environment of the stomach. A study comparing Pancrex V Forte, a conventional enzyme preparation, to three microsphere preparations, Pancrease, Creon, and pancreatin Merck, confirmed the superiority of Pancrease and Creon over Pancrex V Forte and pancreatin Merck with regard to control of symptoms, and nitrogen and fat absorption. Because of differences in the physical characteristics of various microsphere preparations, the dissolution rates of Pancrease, Creon, and pancreatin Merck were compared in vitro. In aqueous buffers, striking differences among the preparations were seen at pH 5.5; whereas only 25% of available lipase was released from Creon, both Pancrease and pancreatin Merck show almost complete dissolution at this pH. Only at pH 6.5 and above do all three preparations show complete dissolution. In duodenal juice, as in aqueous buffers, lipase release from Creon takes place at a lower rate than with the other two preparations until pH 6.0 or higher is attained.(ABSTRACT TRUNCATED AT 250 WORDS)
在过去5年里,利兹地区囊性纤维化(CF)治疗中心对CF患者进行了全面的年度评估,其中包括饮食评估和脂肪吸收研究。将肠溶微球胰酶制剂(微球制剂)与传统酶制剂作为这些患者的治疗药物进行了比较。目前在英国,有两种微球制剂已获许可使用,另外两种产品可能在不久的将来获得许可。这些制剂的成功取决于微球包衣在pH值超过约5.5之前抵抗溶解的能力,从而防止脂肪酶在胃酸环境中失活。一项将传统酶制剂Pancrex V Forte与三种微球制剂Pancrease、Creon和胰酶默克进行比较的研究证实,在症状控制、氮和脂肪吸收方面,Pancrease和Creon优于Pancrex V Forte和胰酶默克。由于各种微球制剂物理特性的差异,对Pancrease、Creon和胰酶默克的溶解速率进行了体外比较。在水性缓冲液中,在pH 5.5时制剂之间出现了显著差异;虽然Creon中只有25%的可用脂肪酶释放出来,但Pancrease和胰酶默克在该pH值下几乎完全溶解。只有在pH 6.5及以上时,三种制剂才会完全溶解。在十二指肠液中,与水性缓冲液一样,直到达到pH 6.0或更高,Creon中脂肪酶的释放速率低于其他两种制剂。(摘要截短于250字)